Comparative Pharmacology
Head-to-head clinical analysis: MICROGESTIN FE 1 5 30 versus OGESTREL 0 5 50 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROGESTIN FE 1 5 30 versus OGESTREL 0 5 50 21.
MICROGESTIN FE 1.5/30 vs OGESTREL 0.5/50-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol (estrogen) and norethindrone acetate (progestin) suppress gonadotropin (FSH, LH) release, preventing ovulation; increase cervical mucus viscosity, inhibiting sperm penetration; alter endometrial development, reducing implantation likelihood.
Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily for 28-day cycles (21 active tablets + 7 ferrous fumarate tablets).
One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Norethindrone: 6-8 hours (terminal); Ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; dosing interval suitable for once-daily administration.
Norgestrel: 24-32 hours; Ethinyl estradiol: 7-12 hours. Clinical context: Steady state achieved after 5-7 days.
Norethindrone: 50-60% renal (as metabolites), 20-40% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal (as glucuronide/sulfate conjugates).
Renal: ~50% (metabolites); Fecal/Biliary: ~50% (metabolites); <1% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive